PMV Pharma Reports Strong Clinical Data for Lead Cancer Drug Rezatapopt, Confirms NDA Timeline, and Extends Cash Runway
PMVP sits 74% above its 52-week low of $0.81.
Summary
PMV Pharmaceuticals reported Q1 2026 financial results, highlighted strong Phase 2 clinical data for rezatapopt in ovarian cancer, announced its publication in the New England Journal of Medicine, and confirmed its cash runway to Q2 2027.
Key Events · Earnings and Guidance · PMVP
-
Strong Phase 2 Clinical Data
Rezatapopt showed an Overall Response Rate (ORR) of 44% (32/72 patients) per investigator assessment, increasing to 46% (34/74) post-data cutoff, with a median Duration of Response (DoR) of 8.2 months in platinum-resistant/refractory ovarian cancer patients.
-
Prestigious Publication
Phase 1 results from the PYNNACLE study were published in the New England Journal of Medicine, highlighting rezatapopt's antitumor activity and proof-of-concept for p53 reactivation.
-
NDA Submission on Track
The company anticipates submitting a New Drug Application (NDA) for rezatapopt in platinum-resistant/refractory ovarian cancer in the first quarter of 2027.
-
Orphan Drug Designation Confirmed
Rezatapopt was granted Orphan Drug Designation by the FDA for the treatment of TP53 Y220C positive ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.
Analysis · PMVP · Life Sciences
This filing provides a significant update on PMV Pharma's lead oncology candidate, rezatapopt, including positive Phase 2 clinical trial results (44-46% ORR, 8.2 months DoR) for platinum-resistant/refractory ovarian cancer, which is crucial for its registrational pathway. The publication in the New England Journal of Medicine adds substantial scientific validation. Furthermore, the company confirmed a cash runway to Q2 2027, providing financial stability for its ongoing development efforts.
At the time of this filing, PMVP was trading at $1.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $74.1M. The 52-week trading range was $0.81 to $1.88. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.